Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 19/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.49 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.49 |
| ▸ | STK16 | O75716 | 1/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | LATS1 | O95835 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369222 | 1.00 | MELK (0.66) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16337639 | 0.89 | MELK (0.58) | MELKDYRK1A | |
| SCHEMBL16369224 | 0.88 | MELK (0.56) | MELKDYRK1A | |
| SCHEMBL16338327 | 0.87 | MELK (0.71) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16338326 | 0.87 | MELK (0.71) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16369227 | 0.86 | MELK (0.75) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16337999 | 0.84 | MELK (0.74) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16338000 | 0.84 | MELK (0.74) | MELKDYRK1ABMPR1BPLK4CIT | |
| SCHEMBL16337362 | 0.84 | MELK (0.54) | MELKDYRK1A | |
| SCHEMBL16369223 | 0.83 | MELK (0.73) | MELKDYRK1ABMPR1BPLK4CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | MELK 1/4885DYRK1A 1584/4885BMPR1B 2446/4885 |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | MELK 1/4885DYRK1A 1584/4885BMPR1B 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.